参考文献/References:
[1].Neumann FJ,Sousa-Uva M,Ahlsson A,et al. 2018 ESC/EACTS Guidelines on myocardial revascularization[J]. Eur Heart J,2019,40(2):87-165.
[2].Klein MD,Lee CR,Stouffer GA. Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy:existing evidence and future directions[J]. Pharmacogenomics,2018,19(13):1039-1046.
[3].Brown SA,Pereira N. Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine [J]. J Pers Med,2018,8(1):1-31.
[4].Ristorto J,Messas N,Marchandot B,et al. Antiplatelet therapy in ACS patients:comparing appropriate P2Y12 inhibition by clopidogrel to the use of new P2Y12 inhibitors[J]. J Atheroscler Thromb,2018,25(8):674-689.
[5].Breet NJ,van Werkum JW,Bouman HJ,et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation[J]. JAMA,2010,303(8):754-762.
[6].Tang XF,Han YL,Zhang JH,et al. Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel[J]. Chin Med J(Engl),2015,128(6):774-779.
[7].Stone GW,Witzenbichler B,Weisz G,et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES):a prospective multicentre registry study[J]. Lancet,2013,382(9892):614-623.
[8].Nishikawa M,Takeda Y,Isomura N,et al.Association between high platelet reactivity following dual antiplatelet therapy and ischemic events in Japanese patients with coronary artery disease undergoing stent implantation[J]. J Atheroscler Thromb,2020,27(1):13-24.
[9].Bitar Kreutz AP. Role of thrombelastography(TEG) in risk assessment and guidance of antithrombotic therapy in patients with coronary artery disease[J]. Drug Dev Res, 2013,74:533-540.
[10].Kreutz RP,Schmeisser G,Maatman B,et al. Fibrin clot strength measured by thrombelastography and outcomes after percutaneous coronary intervention[J]. Thromb Haemost,2017,117(2):426-428.
[11].Bonello L,Mancini J,Pansieri M,et al. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel[J]. J Thromb Haemost,2012,10(10):1999-2005.
[12].Ramstr?m S,S?dergren AL,Tynng?rd N. Platelet function determined by flow cytometry:new perspectives[J]. Semin Thromb Hemost,2016,42(3):268-281.
[13].Guan J,Cong Y,Ren J,et al. Comparison between a new platelet count drop method PL-11,light transmission aggregometry,VerifyNow aspirin system and thromboelastography for monitoring short-term aspirin effects in healthy individuals[J]. Platelets,2015,26(1):25-30.
[14].Zhang JJ,Gao XF,Ge Z,et al. High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention[J]. BMC Cardiovasc Disord,2016,16(1):240.
[15].Zheng YY,Wu TT,Yang Y,et al. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing PCI:a randomized controlled clinical trial[J]. Eur Heart J Cardiovasc Pharmacother,2020,6(4):211-221.
[16].Huo Y,Jeong YH,Gong YJ,et al. 2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI[J]. Sci Bull,2019,64(3):166-179.
[17].Price MJ,Berger PB,Teirstein PS,et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention:the GRAVITAS randomized trial [J]. JAMA,2011,305(11):1097-1105.
[18].Trenk D,Stone GW,Gawaz M,et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents:results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study[J]. J Am Coll Cardiol,2012,59(24):2159-2164.
[19].Collet JP,Cuisset T,Rangé G,et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting[J]. N Engl J Med,2012,367(22):2100-2109.
[20].Cayla G,Cuisset T,Silvain J,et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome(ANTARCTIC):an open-label,blinded-endpoint,randomised controlled superiority trial[J]. Lancet,2016,388(10055):2015-2022.
[21].Sibbing D,Aradi D,Jacobshagen C,et al.Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention(TROPICAL-ACS):a randomised,open-label,multicentre trial[J]. Lancet,2017,390(10104):1747-1757.
[22].Aradi D,Gross L,Trenk D,et al. Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel:a pre-specified exploratory analysis from the TROPICAL-ACS trial[J]. Eur Heart J,2019,40(24):1942-1951.
[23].Cuisset T,Deharo P,Quilici J,et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome:the TOPIC(timing of platelet inhibition after acute coronary syndrome) randomized study[J]. Eur Heart J,2017,38(41):3070-3078.
[24].Deharo P,Quilici J,Camoin-Jau L,et al. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study[J]. JACC Cardiovasc Interv,2017,10(24):2560-2570.
[25].Jeong YH. “East asian paradox”:challenge for the current antiplatelet strategy of “one-guideline-fits-all races” in acute coronary syndrome[J]. Curr Cardiol Rep,2014,16(5):485.
[26].徐俊波,黄刚,蔡琳,等. 老老年患者抗血小板治疗的循证临床实践[J]. 心血管病学进展,2019,40(8):1123-1126.